## genomics -online.com





## Human MYCL2 CRISPR gRNA + Cas9 in Lenti Particles

| Overview              |   |
|-----------------------|---|
| Quantity:             | 3 x 300 μL  |
| Gene:                 | MYCL2   |
| Species:              | Human   |
| Insert:               | gRNA + Cas9   |
| Vector:               | Lentiviral Vector   |
| Application:          | Genome Editing with Engineered Nucleases (GEEN), Protein Expression (PExp)                    |
| Product Details       |   |
| Purpose:              | Set of 3 gRNA against MYCL2 in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA and |
|                       | Cas9 in a single vector)  |
| Vector Backbone:      | pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro   |
| Promoter:             | U6 Promoter, SFFV Promoter  |
| Selectable Marker:    | Puromycin   |
| Bacterial Resistance: | Ampicillin  |
| Expression Type:      | Stable, Transient   |
| Sequence:             | Sequence available upon placing order   |
| Specificity:          | GRNAs are designed for use with Cas9 Nuclease only.   |
|                       | Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority |
|                       | of cells, except ES cells or iPS cells.   |
| Sequencing Primer:    | U6 Forward Primer: 5'TACGTCCAAGGTCGGGCAGGAAGA3'   |
| Components:           | Lentiviral particles with a set of 3 gRNAs (3 x 300 μL) covering different sequences of MYCL2 |

## **Target Details**

| Gene:             | MYCL2                  |
|-------------------|------------------------|
| Alternative Name: | MYCL2 (MYCL2 Products) |
| NCBI Accession:   | NG_009866              |

| Application Details |  |
|---------------------|--|
| Application Notes:  | Recommended for quality control: Restriction Enzyme Digest and Sequencing              |
| Restrictions:       | For Research Use only  |
| Handling            |  |
| Format:             | Viral Particles  |
| Storage:            | -80 °C   |
| Expiry Date:        | 12 months  |
| Publications        |  |
| Product cited in:   | Johnson Drugan Miller Evans: "29" in: Vol. 1363 Jesus Nuclais saids research pp. 29-30 |

Product cited in: Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, (
1991)